Frankfurt
03.08.26 | 08:07
23,840 Euro
+1,62 % +0,380
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 24,020 | 24,440 | 12:09 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10:02 | XVIVO Perfusion AB: XVIVO Granted Additional Patient Enrollment in the US PRESERVE CAP Study for XVIVO Heart Assist Transport | 195 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / August 3, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - XVIVO announces that the US Food and Drug Administration (FDA) has granted the company approval... ► Artikel lesen | |
| XVIVO PERFUSION Aktie jetzt für 0€ handeln | |||||
| 14.07. | Xvivo Perfusion AB (publ) reports Q2 results | 2 | Seeking Alpha | ||
| 14.07. | Xvivo Perfusion AB Q2 Profit Rises | 2 | RTTNews | ||
| 14.07. | XVIVO übertrifft im Q2 die Umsatzerwartungen dank starkem Thorax-Geschäft | - | Investing.com Deutsch | ||
| 14.07. | XVIVO Perfusion AB: Interim Report January - June 2026 | 350 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 14, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Second quarter 2026 (Apr-Jun)Net sales amounted to SEK 239.0 million (178.3), corresponding to a growth... ► Artikel lesen | |
| 09.07. | OneLegacy Partners with XVIVO and Perfusion Solution to Launch the First Ex Vivo Lung Perfusion (EVLP) Center in the Western U.S. | 332 | Business Wire | OneLegacy, the nonprofit organ procurement organization serving Southern California, announced the launch of the first in-house Ex Vivo Lung Perfusion (EVLP) program at an organ procurement organization... ► Artikel lesen | |
| 26.06. | XVIVO Perfusion AB: Conference call on Interim Report April-June 2026 | 405 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / June 26, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report April-June 2026. The... ► Artikel lesen | |
| 18.05. | XVIVO Perfusion AB: Regulatory Derogation and Reimbursement in France Enable Life-Saving Use of XVIVO's Heart Technology | 376 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / May 18, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Hôpital La Pitié-Salpêtrière (Sorbonne University) in Paris, France, has, since the approval of... ► Artikel lesen | |
| 27.04. | Bulletin from Annual General Meeting in XVIVO Perfusion AB | 311 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 27, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV):The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion... ► Artikel lesen | |
| 24.04. | Xvivo Perfusion AB (publ) GAAP EPS of SEK1.15, revenue of SEK241M | 1 | Seeking Alpha | ||
| 24.04. | XVIVO Perfusion AB: Interim Report January - March 2026 | 195 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 24, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2026 (Jan-Mar)Net sales amounted to SEK 241.0 million (218.6), corresponding to growth... ► Artikel lesen | |
| 24.04. | Xvivo Perfusion AB: Interim Report January - March 2026 | 208 | GlobeNewswire (Europe) | First quarter 2026 (Jan-Mar)• Net sales amounted to SEK 241.0 million (218.6), corresponding to growth of 10 percent in SEK.• Organic growth was 23 percent in local currencies. Excluding revenue from... ► Artikel lesen | |
| 22.04. | XVIVO Perfusion AB: XVIVO Presents Encouraging Results From First Clinical Trial Using Hypothermic Oxygenated Perfusion In Direct Procurement DCD Heart Transplantation | 478 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, the results from the HOPE-at-Heart clinical trial (NCT06485596) were presented at the ISHLT... ► Artikel lesen | |
| 22.04. | XVIVO Perfusion AB: Preliminary One-Year Follow-up Data From the US Preserve Trial for XVIVO's Heart Technology Presented at ISHLT in Toronto | 426 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, preliminary one-year follow-up data from the US PRESERVE trial of XVIVO's investigational... ► Artikel lesen | |
| 22.04. | Late-Breaking Data from PRESERVE Trial Evaluates XVIVO's HOPE Preservation Approach in Heart Transplantation | 449 | Business Wire | Preliminary results suggest potential to support extended preservation time and donor heart utilization XVIVO, a global medtech company in the organ transplant industry, today announced late-breaking... ► Artikel lesen | |
| 17.04. | XVIVO Perfusion AB: Conference Call on Interim Report January-March 2026 | 324 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 17, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2026.... ► Artikel lesen | |
| 16.04. | XVIVO Perfusion AB: The 12-Month Follow-up Results from XVIVO's European Multicenter Heart Trial is Now Published in the European Heart Journal | 335 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 16, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - At last year's ISHLT congress, in April 2025, the one-year results from the European multicenter... ► Artikel lesen | |
| 02.04. | Xvivo Perfusion AB (publ) GAAP EPS of SEK 0.80, revenue of SEK 812.2M | 4 | Seeking Alpha | ||
| 01.04. | XVIVO Perfusion AB: Annual Report 2025 | 402 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 1, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today XVIVO Perfusion AB (publ) publish the Annual Report for 2025. The Annual Report is attached... ► Artikel lesen | |
| 19.03. | Notice To Attend the Annual General Meeting in XVIVO Perfusion Ab | 677 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / March 19, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice of... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARL ZEISS MEDITEC | 31,840 | +4,39 % | EQS-AFR: Carl Zeiss Meditec AG: Vorabbekanntmachung über die Veröffentlichung von Quartalsberichten und Quartals-/Zwischenmitteilungen | EQS Vorabbekanntmachung Finanzberichte: Carl Zeiss Meditec AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Carl Zeiss Meditec AG: Vorabbekanntmachung... ► Artikel lesen | |
| ECKERT & ZIEGLER | 13,730 | +0,88 % | Turnaround-Aktien mit fast 200 % Kurspotenzial! Renk, Eckert & Ziegler, Power Metallic Mines! | Rund 50 % hat die Renk-Aktie seit Oktober 2025 verloren. Ist jetzt die Chance zum Einstieg gekommen? Jefferies sieht den fairen Wert immerhin bei 60 EUR. Die kommenden Halbjahreszahlen sollten überzeugen... ► Artikel lesen | |
| INTUITIVE SURGICAL | 309,70 | +1,06 % | Intuitive Surgical: Was UBS nach dem Rücksetzer sieht | ||
| RHOEN-KLINIKUM | 12,900 | 0,00 % | Delegation aus der Ukraine besucht RHÖN-KLINIKUM Campus Bad Neustadt / Fokus auf Telemedizin | Bad Neustadt a. d. Saale (ots) - Campus Bad Neustadt als ausgewählte Station des internationalen Programms "Bayern - Fit for Partnership"Eine 20-köpfige Delegation aus Fach- und Führungskräften sowie... ► Artikel lesen | |
| BICO GROUP | 1,316 | 0,00 % | BICO Group AB: Bulletin from the Annual General Meeting in BICO Group AB (publ) | The following resolutions were passed at the Annual General Meeting (the "AGM") of BICO Group AB (publ) ("BICO" or the "Company") held today on 7 May 2026 in Gothenburg, Sweden.
Adoption of Income Statement... ► Artikel lesen | |
| M1 KLINIKEN | 18,840 | -0,84 % | Dividendenbekanntmachungen (09.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,63 USD 1,4275 EUR ALIMENTATION COUCHE-TARD INC CA01626P1484 0,215 CAD 0,1328 EUR ANPARIO PLC GB00B3NWT178 0... ► Artikel lesen | |
| BAXTER | 22,990 | +1,37 % | ROUNDUP/Aktien New York Schluss: Nasdaq stark erholt - Microsoft-Kursfeuerwerk | NEW YORK (dpa-AFX) - Starke Geschäftszahlen von Microsoft haben der Nasdaq-Börse am Donnerstag eine rasante Erholung beschert. Schnäppchenjäger übernahmen dort das Ruder. Der Nasdaq 100 konterte eine... ► Artikel lesen | |
| ASENSUS SURGICAL | - | - | Karl Storz to fully integrate Asensus, discontinue Senhance, Luna robots | ||
| JD HEALTH INTERNATIONAL | 4,450 | +2,74 % | JD HEALTH (06618): DATE OF BOARD MEETING | ||
| COOPER COMPANIES | 63,42 | +1,16 % | CooperCompanies Announces Release Date for Third Quarter 2026 | ||
| LIFEWARD | 7,110 | 0,00 % | Lifeward Ltd.: Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing | HUDSON, Mass. and YOKNEAM ILLIT, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio... ► Artikel lesen | |
| BONESUPPORT | 21,100 | +4,87 % | Bonesupport Holding AB: BONESUPPORT HOLDING AB (publ) - publishes Q2 2026 interim report | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2026.
"Strong growth and improved operating... ► Artikel lesen | |
| ONWARD MEDICAL | 2,380 | +1,93 % | ONWARD Medical NV: ONWARD Medical Reports First Quarter 2026 Results with Strong Commercial Momentum and Key Clinical Milestones | EINDHOVEN, the Netherlands, May 26, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD - US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function... ► Artikel lesen | |
| COMMUNITY HEALTH SYSTEMS | 2,400 | 0,00 % | Community Health Systems forecasts 2026 adjusted EBITDA of $1.3B-$1.375B amid softer elective surgeries and higher uninsured volumes | ||
| RAMSAY HEALTH CARE | 27,000 | 0,00 % | RAMSAY SANTE: Press Release - Refinancing new steps forward | PRESS RELEASE Paris, 22nd July 2026 New steps in connection with Ramsay Santé contemplated free-float expansion: Ramsay Santé successfully completes its senior debt refinancing and convenes a Capital... ► Artikel lesen |
XVIVO PERFUSION AB gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von +0,380 (+1,62 %) liegt der Kurs bei 23,840 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XVIVO PERFUSION AB finden Sie auf Wallstreet Online.